Researchers at Albert Einstein College of Medicine published preclinical results showing a modular protein scaffold that links IL‑7, IL‑15 and IL‑21 during CAR‑T manufacture generated cells with markedly improved longevity and self‑renewal in mouse models (Science Advances). The engineered scaffold—HCW9206—produced CAR‑T products enriched in T memory stem cells, yielding longer tumor control and improved suppression of HIV in animal studies compared with standard activation protocols. The work addresses the clinically relevant challenge of CAR‑T persistence, where loss of durability contributes to relapse; T memory stem cells are a cell subset linked to long‑term engraftment and proliferative capacity. If manufacturing‑scale translation succeeds, the approach could be applied across multiple cell‑therapy programs to extend clinical benefit.